https://www.selleckchem.com/products/CHIR-258.html
54, 95% CI 0.28-1.01; invitro fertilization HR 0.65, 95% CI 0.39-1.08; and combined treatments HR 1.23, 95% CI 0.49-3.06). An increased breast cancer risk was associated with paternal origin of the mutation (HR 1.43, 95% CI 1.17-1.75) and use of oral contraceptives for 5 years (HR 1.62, 95% CI 1.27-2.06) in both BRCA1 and BRCA2 mutation carriers. Ovarian cancer risk was decreased with the use of any oral contraceptive (HR 0.61; 95% CI 0.46-0.82). Fertility treatment for BRCA1/2 mutation carriers is not associated with a discernible
Like
Comment
Share
